EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ANXA1 / FPR Signaling Contribute to Paclitaxel Resistance in Ovarian Cancer Through PI3K / AKT ‐Associated PGC1α Regulation

Zhou Li iD, Jiang Mingrui iD, Zhou Yueyang iD, Qi Hang iD, Liu Qing iD, Yan Xiaoyu iD, Yu Huimei iD, Xia Meihui iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Zhou Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, Jilin, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Drug Resistance, Neoplasm, Paclitaxel, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Provincial Research Foundation for the Development of Science and Technology Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ovarian cancer has the highest mortality among gynecologic malignancies, and acquired resistance to paclitaxel severely limits its clinical efficacy.

Aims

This study aimed to investigate whether the ANXA1/FPR axis contributes to paclitaxel resistance in ovarian cancer and to elucidate the underlying molecular mechanisms. Methods and Results Using the ANXA1 mimetic peptide Ac2‐26 and the FPR antagonist Boc2, we provided pharmacological evidence that activation of the ANXA1/FPR axis promotes paclitaxel resistance in ovarian cancer cells. Mechanistically, ANXA1/FPR signaling activated the PI3K/AKT pathway and upregulated PGC1α, leading to enhanced mitochondrial biogenesis and adaptive energy metabolism remodeling, which in turn prevented paclitaxel‐induced cell death.

Conclusion

Our findings suggest that the ANXA1/FPR/PI3K/AKT/PGC1α axis may represent a potential therapeutic target for overcoming paclitaxel resistance in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsDrug Resistance, NeoplasmPaclitaxelAntineoplastic Agents, PhytogenicAnnexin A1Receptors, Formyl PeptideHumansFemaleSignal TransductionPhosphatidylinositol 3-KinaseOncogene Protein v-aktPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaGene Expression Regulation, NeoplasticCell Line, TumorAnimalsMicePeptides

Stichwörter der Autor:innen

ANXA1PI3K/AKT/PGC1αovarian cancerpaclitaxel resistance

Substanzen

PaclitaxelAntineoplastic Agents, PhytogenicANXA1 protein, humanAnnexin A1Receptors, Formyl PeptidePhosphatidylinositol 3-KinaseOncogene Protein v-aktPPARGC1A protein, humanPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaannexin A1 peptide (2-26)

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, Jilin, China.
  • Department of Pathophysiology, School of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.

ORCID-Profile: Zhou Li, Jiang Mingrui, Zhou Yueyang, Qi Hang, Liu Qing, Yan Xiaoyu, Yu Huimei, Xia Meihui

Förderung

  • Jilin Provincial Research Foundation for the Development of Science and Technology Projects

Zitieren

APA

Li, Z., Mingrui, J., Yueyang, Z., Hang, Q., Qing, L., Xiaoyu, Y., Huimei, Y., & Meihui, X. (2026). ANXA1 / FPR Signaling Contribute to Paclitaxel Resistance in Ovarian Cancer Through PI3K / AKT ‐Associated PGC1α Regulation. Cancer Reports. https://doi.org/10.1002/cnr2.70637

Vancouver

Li Z, Mingrui J, Yueyang Z, Hang Q, Qing L, Xiaoyu Y, et al. ANXA1 / FPR Signaling Contribute to Paclitaxel Resistance in Ovarian Cancer Through PI3K / AKT ‐Associated PGC1α Regulation. Cancer Reports. 2026. doi:10.1002/cnr2.70637

BibTeX
@article{Li2026,
  author = {Li, Zhou and Mingrui, Jiang and Yueyang, Zhou and Hang, Qi and Qing, Liu and Xiaoyu, Yan and Huimei, Yu and Meihui, Xia},
  title = {ANXA1 / FPR Signaling Contribute to Paclitaxel Resistance in Ovarian Cancer Through PI3K / AKT ‐Associated PGC1α Regulation},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70637}
}
Kostenlos starten →